Axel U Dignass

43PUBLICATIONS
107CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Ngā rongoā me ngā whakamaimoa o te Māori (Māori medicine and treatments)Disease surveillanceCancer therapy (excl. chemotherapy and radiation therapy)Nutritional epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (43)

|May 20, 2026
Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus.

|May 11, 2026
Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial.

|Mar 27, 2026
Timing matters: recommendations for outcome assessment in real-world evidence studies of Crohn's disease.

Paula Leão Moreira, Axel Dignass, Maria Manuela Estevinho

|Mar 04, 2026
Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study.

Bruce E Sands, David B Clemow, Geert D'Haens

|Jul 12, 2025
Efficacy and Safety of Infliximab and Vedolizumab Maintenance Therapy in Patients with Crohn's Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis.

Bruce E Sands, Laurent Peyrin-Biroulet, Stefan Schreiber

|Jun 27, 2025
Gaps between European Crohn's and Colitis Organisation quality standards of care and the real world on diagnosis and monitoring inflammatory bowel disease across Europe: results from the E-QUALITY survey.

Gionata Fiorino, Catarina Fidalgo, Michel Adamina

Pageof 8

Frequent Collaborators

11 joint publications

Jürgen Stein

8 joint publications

Ayşegül Aksan

8 joint publications

Silvio Danese

8 joint publications

Laurent Peyrin-Biroulet